Centrus Energy Corp (LEU) Stock Price Today
Basilea presents new data on antifungals fosmanogepix, isavuconazole, and antibiotic ceftobiprole at IDWeek 2026
Basilea Pharmaceutica announced new clinical and activity data for its antifungal drugs fosmanogepix and isavuconazole, as well as the antibiotic ceftobiprole, to be presented at IDWeek 2026 in Washington D.C. Highlights include pediatric data from f...
Gainsight launches AI-native Atlas managing $75M ARR and new value-based pricing for customer retention.
Gainsight introduced its AI-native services business, Atlas, which manages over $75 million in annual recurring revenue (ARR) by handling long-tail customer renewals with AI agents and human managers. The company also announced a shift to value-based...
Oculis to present new Phase 2 biomarker data on Privosegtor for optic neuritis at ACTRIMS-ECTRIMS 2026
Oculis Holding AG will present new biomarker analyses from its Phase 2 ACUITY trial of Privosegtor, a potential neuroprotective therapy for optic neuritis, at the 10th Joint ACTRIMS-ECTRIMS Meeting in October 2026. The data focus on plasma neurofilam...
Equinor buys 389,058 shares in ongoing buy-back for employee incentive programs.
Equinor ASA announced it purchased 389,058 of its own shares on October 15, 2026, at an average price of NOK 429.24 per share as part of its ongoing buy-back program. The program, running from February 13, 2026, to January 15, 2027, aims to buy up to...
Equinor completes third tranche of 2026 share buy-back, acquiring 540,275 shares at NOK 425.48 each.
Equinor ASA has completed transactions under the third tranche of its 2026 share buy-back program, purchasing 540,275 shares between October 12 and 16 at an average price of NOK 425.48 per share. This tranche started on July 23 and will run until Oct...
Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
RoseNose Investing highlights undervalued high-yield dividend stocks, warns against overvalued energy names.
RoseNose Investing Group's latest review identifies 15 most undervalued and 15 most overvalued dividend stocks based on 52-week high/low analysis. Energy stocks like ExxonMobil (XOM), Shell (SHEL), and Chevron (CVX) have moved into overvalued territo...
Oracle and AstraZeneca team up to use AI and real-world data to speed up clinical trials and improve patient care.
Oracle and AstraZeneca have entered a collaboration to combine AstraZeneca's scientific expertise with Oracle's AI, cloud, and real-world data capabilities. The partnership aims to accelerate clinical trials by helping clinicians identify eligible pa...
Ambarella grows 13.2% in Q2 FY2027, shifting to edge AI with new chips but faces profit and cash flow challenges.
Ambarella is transitioning from security camera chips to edge AI, expanding into automotive, robotics, and smart security with new 5nm chips and the X7 AI accelerator. In Q2 FY2027, revenue rose 13.2% to $108.1 million, driven by automotive and IoT s...
Bank Indonesia likely to hike rates amid MSCI downgrade fears and rupiah pressure
Bank Indonesia faces pressure to raise its benchmark interest rate on Wednesday to stabilize the rupiah after MSCI warned it might downgrade Indonesia's stock market from emerging-market status. This warning triggered a sharp selloff in stocks and th...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.